Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Her2-LAMP
- Development stage
- Preclinical
- Lead developer
- Immunomic Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
Her2-LAMP is an investigational therapeutic DNA plasmid cancer vaccine developed by Immunomic Therapeutics in collaboration with Duke University. Utilizing Immunomic's proprietary UNITE (UNiversal Intracellular Targeted Expression) platform, the vaccine encodes the human epidermal growth factor receptor 2 (HER2/ErbB2) tumor-associated antigen fused in-frame with lysosomal-associated membrane protein 1 (LAMP-1). This fusion directs the expressed HER2 antigen to the endolysosomal compartment of antigen-presenting cells, enhancing antigen processing and presentation via both MHC class II and MHC class I pathways. This mechanism stimulates robust, polyfunctional HER2-specific CD4+ and CD8+ T cell responses as well as humoral antibody responses, promoting tumor regression and infiltration of activated T cells into the tumor microenvironment. It is primarily being investigated for the treatment of HER2-expressing cancers, such as HER2-positive breast cancer.
- Other names
- HER2-LAMPHER-2-LAMPHER 2-LAMPHER2-LAMP DNA vaccineHER-2-LAMP DNA vaccineHER 2-LAMP DNA vaccineHER2/Neu-LAMPHer2/Neu-LAMP DNA vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)LAMP1 (Lysosomal-associated membrane protein 1)
Beyond the preview
Go deeper on Her2-LAMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Her2-LAMP.